|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
27
|
|
pubmed:dateCreated |
1997-11-10
|
|
pubmed:abstractText |
BCG therapy is the reference adjuvant treatment for multiple and voluminous or recurrent superficial bladder cancer and can cause specific complications. We assessed the frequency and therapeutic modalities involved associated with such complications in a personal retrospective series of patients.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0755-4982
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1284-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9380636-Adjuvants, Immunologic,
pubmed-meshheading:9380636-Administration, Intravesical,
pubmed-meshheading:9380636-Adult,
pubmed-meshheading:9380636-Aged,
pubmed-meshheading:9380636-Aged, 80 and over,
pubmed-meshheading:9380636-BCG Vaccine,
pubmed-meshheading:9380636-Chemotherapy, Adjuvant,
pubmed-meshheading:9380636-Female,
pubmed-meshheading:9380636-Follow-Up Studies,
pubmed-meshheading:9380636-Humans,
pubmed-meshheading:9380636-Male,
pubmed-meshheading:9380636-Middle Aged,
pubmed-meshheading:9380636-Risk Factors,
pubmed-meshheading:9380636-Urinary Bladder Neoplasms
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
[Risk of complications during endovesical treatment with BCG for superficial tumor of the bladder].
|
|
pubmed:affiliation |
Service d'Urologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
